MX369664B - Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer. - Google Patents

Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer.

Info

Publication number
MX369664B
MX369664B MX2015009409A MX2015009409A MX369664B MX 369664 B MX369664 B MX 369664B MX 2015009409 A MX2015009409 A MX 2015009409A MX 2015009409 A MX2015009409 A MX 2015009409A MX 369664 B MX369664 B MX 369664B
Authority
MX
Mexico
Prior art keywords
inorganic nanoparticles
ionizing radiations
combination
treating cancer
nanoparticles
Prior art date
Application number
MX2015009409A
Other languages
English (en)
Other versions
MX2015009409A (es
Inventor
Borghi Elsa
Levy Laurent
Pottier Agnès
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MX2015009409A publication Critical patent/MX2015009409A/es
Publication of MX369664B publication Critical patent/MX369664B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1087—Ions; Protons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1089—Electrons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente solicitud se refiere a nanopartículas inorgánicas activables que pueden usarse en el campo de la salud, en particular en el de la salud humana, para perturbar, alterar o destruir células, tejidos u órganos cancerosos diana. Más particularmente se refiere a nanopartículas que pueden generar un efecto terapéutico sorprendentemente eficaz, cuando se concentran dentro del tumor y se exponen a radiaciones ionizantes. La invención también se refiere a composiciones farmacéuticas que comprenden una población de nanopartículas, tal como se han definido anteriormente, así como a sus usos.
MX2015009409A 2013-01-25 2014-01-24 Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer. MX369664B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756533P 2013-01-25 2013-01-25
EP13305087 2013-01-25
PCT/EP2014/051367 WO2014114732A1 (en) 2013-01-25 2014-01-24 Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Publications (2)

Publication Number Publication Date
MX2015009409A MX2015009409A (es) 2016-03-16
MX369664B true MX369664B (es) 2019-11-14

Family

ID=47710064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009409A MX369664B (es) 2013-01-25 2014-01-24 Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer.

Country Status (23)

Country Link
US (4) US10098952B2 (es)
EP (1) EP2948179B1 (es)
JP (2) JP6619231B2 (es)
KR (2) KR102385193B1 (es)
CN (1) CN105120897B (es)
AR (1) AR094577A1 (es)
AU (1) AU2014209899B2 (es)
BR (1) BR112015017490A2 (es)
CA (2) CA3179586A1 (es)
CY (1) CY1121838T1 (es)
EA (1) EA034242B1 (es)
HK (1) HK1216609A1 (es)
IL (1) IL239767B (es)
MA (1) MA38318A1 (es)
MX (1) MX369664B (es)
PL (1) PL2948179T3 (es)
RS (1) RS59042B1 (es)
SG (1) SG11201505277VA (es)
SI (1) SI2948179T1 (es)
TW (1) TW201442726A (es)
UA (1) UA116007C2 (es)
WO (1) WO2014114732A1 (es)
ZA (1) ZA201505510B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012351537B2 (en) 2011-12-16 2017-03-02 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
US10098952B2 (en) 2013-01-25 2018-10-16 Nanobiotix Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
EP2886128A1 (en) * 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
WO2016189125A1 (en) 2015-05-28 2016-12-01 Nanobiotix Nanoparticles for use as a therapeutic vaccine
IL267407B2 (en) * 2016-12-21 2024-02-01 Nanobiotix Nanoparticles for use to improve brain performance or treat stress
AU2017384425B2 (en) * 2016-12-21 2023-08-31 Nanobiotix Nanoparticles for use for treating a neuronal disorder
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
EP3654976A1 (en) * 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
WO2021011496A1 (en) * 2019-07-12 2021-01-21 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
US20220249389A1 (en) * 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
CA3139714A1 (en) 2019-07-12 2021-01-21 Wassana Yantasee Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
WO2021215952A1 (ru) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Способ получения частиц бактериофагов семейства levivirus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006244A2 (en) 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
WO2002040042A2 (en) * 2000-11-20 2002-05-23 Oncolytics Biotech, Inc. Method for optimally delivering virus to a solid tumor mass
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
FR2884149B1 (fr) * 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
EP2130553A1 (en) * 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US8395131B2 (en) * 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (en) 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
WO2011127061A1 (en) 2010-04-05 2011-10-13 Nanospectra Biosciences, Inc. Enhancement of radiation therapy by targeted high-z nanoparticles
AU2012351537B2 (en) 2011-12-16 2017-03-02 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
US10098952B2 (en) 2013-01-25 2018-10-16 Nanobiotix Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Also Published As

Publication number Publication date
SI2948179T1 (sl) 2019-09-30
EP2948179A1 (en) 2015-12-02
PL2948179T3 (pl) 2019-10-31
IL239767A0 (en) 2015-08-31
IL239767B (en) 2018-10-31
US11819548B2 (en) 2023-11-21
US20190008962A1 (en) 2019-01-10
KR102225239B1 (ko) 2021-03-09
KR20150108923A (ko) 2015-09-30
CA2897362C (en) 2023-02-14
JP2016505061A (ja) 2016-02-18
US10098952B2 (en) 2018-10-16
HK1216609A1 (zh) 2016-11-25
KR20210027536A (ko) 2021-03-10
EA034242B1 (ru) 2020-01-21
CA2897362A1 (en) 2014-07-31
JP6619231B2 (ja) 2019-12-11
BR112015017490A2 (pt) 2017-07-11
RS59042B1 (sr) 2019-08-30
SG11201505277VA (en) 2015-08-28
MX2015009409A (es) 2016-03-16
CN105120897A (zh) 2015-12-02
ZA201505510B (en) 2016-12-21
CN105120897B (zh) 2017-12-05
EP2948179B1 (en) 2019-06-19
AR094577A1 (es) 2015-08-12
US20210283256A1 (en) 2021-09-16
CA3179586A1 (en) 2014-07-31
KR102385193B1 (ko) 2022-04-12
CY1121838T1 (el) 2020-07-31
UA116007C2 (uk) 2018-01-25
AU2014209899A1 (en) 2015-07-23
US20240100163A1 (en) 2024-03-28
WO2014114732A1 (en) 2014-07-31
TW201442726A (zh) 2014-11-16
EA201591378A1 (ru) 2016-04-29
US11020480B2 (en) 2021-06-01
MA38318A1 (fr) 2017-02-28
JP2018168162A (ja) 2018-11-01
US20150374818A1 (en) 2015-12-31
AU2014209899B2 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
MX2015009409A (es) Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2019001920A (es) Arn la terapia contra el cancer.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2019010601A (es) Terapia de combinacion para tratar cancer.
NZ749218A (en) Androgen receptor modulator and uses thereof
SG10201902664RA (en) Combination therapy for treating cancer
WO2015009726A3 (en) Medical uses of cd38 agonists
WO2016043874A3 (en) Combination therapy for treating cancer
MX2016009069A (es) Conjugados de anticuerpo-farmaco (adcs) que contienen duocarmicina para usarse en el tratamiento de cancer endometrial.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2015012922A (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
MX2023007706A (es) Nanoparticulas para su uso como vacuna terapeutica.
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
NZ709685A (en) Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2019014934A (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
MX2019014842A (es) Uso de una combinación de ivosidenib y radiación para tratar gliomas.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.

Legal Events

Date Code Title Description
FG Grant or registration